ID: h-94e73015
Hypothesis
CSF1R Partial Agonism Combined with TREM2 Activation for ALS Neuroprotection
Premature investment.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 4 support✗ 4 oppose
✓ All Quality Gates Passed
🧪 Overview
Premature investment. The Expert identifies that no validated partial CSF1R agonist exists—creating partial agonism for a receptor kinase requires allosteric modulators with precise cooperativity values that are chemically non-trivial. Orion Corporation's LIGAMENT trial (CSF1R inhibitor in ALS) will read out in 2025 and is critical; if inhibition worsens disease, partial agonism logic is validated, but if inhibition helps, the entire axis is challenged. TREM2 antibodies in ALS (Alector) provide parallel development path.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["Testosterone/ANDROGEN RECEPTOR Axis<br/>Neuronal Androgen Binding"]
B["AR Nuclear Translocation<br/>Coactivator Recruitment and Hormonal Ligand"]
C["TM4SF5 and CD82 Expression<br/>Senescent Cell Surface Marker Induction"]
D["Senolytic Target Engagement<br/>p53-Dependent Apoptosis in SASP Cells"]
E["Inflammatory Niche Remodeling<br/>SASP Factor Clearance"]
F["Neurodegenerative Niche Improvement<br/>Reduced Inflammatory Tone"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style D fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#1b5e20,stroke:#81c784,color:#81c784⚖️ Evidence
⚖️ Evidence Matrix4 supports4 contradicts
Supports
TREM2 deficiency worsens ALS pathology in SOD1 mice via impaired debris clearance
Supports
Synergistic targeting of CSF1R-TREM2 axis promotes neuroprotective microglial states
Supports
Pexidartinib (CSF1R inhibitor) approved for TGCT; BLZ945 tool compound available
Contradicts
CSF1R has dose-dependent signaling bifurcation; partial agonism lacks precise molecular definition
Contradicts
TREM2 expression is heterogeneous in ALS microglia with some TREM2-correlated neurotoxic signatures
Contradicts
SOD1G93A model represents only ~2% of human ALS cases; TDP-43 pathology may differ
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — CSF1R
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for CSF1R Partial from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for CSF1R Partial.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0010
Events (7d)
0
Price History
▼1.2%💾 Resource Usage
LLM Tokens
32,048
$0.0961
Total Cost
$0.0961
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF ALS patients treated with TREM2-activating antibodies (AL001 or AL002, Alector Phase 2 trials) show statistically significant reduction or stabilization of cerebrospinal fluid neurofilament light c | CSF NfL levels decrease by ≥20% from baseline or remain ≤10% above baseline in TREM2 antibody treatment group vs ≥40% increase in placebo group at 12 months, wi | — no observation — | pending | 0.25 |
| IF ALS patients receiving CSF1R inhibitor (PLX3007) in the Orion LIGAMENT trial demonstrate ≥20% faster disease progression (ALSFRS-R slope increase) compared to placebo over 24 weeks, THEN this outco | ALSFRS-R total score decline rate of ≥1.2 points/month in treatment arm vs ≤1.0 points/month in placebo arm (20% difference), with corresponding plasma neurofil | — no observation — | pending | 0.35 |
🔮 Falsifiable Predictions (2)
pendingconf 35%
IF ALS patients receiving CSF1R inhibitor (PLX3007) in the Orion LIGAMENT trial demonstrate ≥20% faster disease progression (ALSFRS-R slope increase) compared to placebo over 24 weeks, THEN this outcome would validate the partial agonism approach over complete inhibition as a therapeutic strategy fo
Predicted outcome: ALSFRS-R total score decline rate of ≥1.2 points/month in treatment arm vs ≤1.0 points/month in placebo arm (20% difference), with corresponding plasm
Falsification: CSF1R inhibition produces neutral (difference <10% on ALSFRS-R slope) or improved outcomes in the LIGAMENT trial, indicating the entire CSF1R-TREM2 signaling axis is not a valid target for ALS neuropr
pendingconf 25%
IF ALS patients treated with TREM2-activating antibodies (AL001 or AL002, Alector Phase 2 trials) show statistically significant reduction or stabilization of cerebrospinal fluid neurofilament light chain (NfL) levels compared to baseline at 12 months while matched placebo cohorts show progressive N
Predicted outcome: CSF NfL levels decrease by ≥20% from baseline or remain ≤10% above baseline in TREM2 antibody treatment group vs ≥40% increase in placebo group at 12
Falsification: TREM2-activating antibodies show no significant difference in CSF NfL trajectories between treatment and placebo arms, or demonstrate increased neuroinflammatory markers, indicating TREM2 activation a
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.